Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study

• DOI: 10.1016/j.pan.2022.06.004
• Publication Date: 2022-06-09T20:10:04Z
• Authors: Shun Tezuka; Makoto Ueno; Satoshi Kobayashi; Tomomi Hamaguchi; Yui Yamachika; Ritsuko Oishi; Shuhei Nagashima; Taito Fukushima; Manabu Morimoto; Maeda Shin
• Keywords: FOLFIRI; FOLFIRINOX; Regimen; Chemotherapy regimen

The preferred regimen for unresectable pancreatic cancer following gemcitabine-based chemotherapy is not well-established. This study compared the efficacy of (ⅰ) liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) versus modified FOLFIRINOX (mFFX) and (ⅱ) nal-IRI/5-FU/LV FOLFIRI, respectively, safety three regimens each other, as second-line chemotherapies cancer.This was a retrospective single-center analysis all patients who were administered nal-IRI/5-FU/LV, mFFX, or FOLFIRI from December 2014 to July 2021 cancer. primary endpoint overall survival (OS) patients, excluding those with locally advanced Regarding safety, we assessed incidence grade ≥3 adverse events interest in patients.A total 137 (nal-IRI/5-FU/LV, n = 55; 39; 43) included. median OS group, mFFX group 7.4, 11.8, 8.4 months, respectively. Compared groups displayed hazard ratio 0.66 [95% confidence interval 0.40-1.08] 0.87 0.55-1.39], In treatment-related tended be low among groups.Given trend toward longer lower both well can treatment options